David Nutt

David John Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. He is the chairman of Drug Science, a non-profit which he founded in 2010 to provide independent, evidence-based information on drugs.

115. Six years of medical cannabis in the UK with Dr Leon Barron, Dr Callie Seaman and Michael Sassano

What is the UK medical cannabis industry looking like in 2024? We are 6 years on from legalisation of cannabis-based medical products in the UK...

Psychedelic Exceptionalism Harms People Who Take Antidepressants

Since they were launched in the late 1980s, antidepressant selective serotonin reuptake inhibitors (SSRIs) like Prozac have become incredibly popular in developed countries as the...

108. Psychedelic Education in the UK with Dr Duncan Still

In this episode, David Nutt meets with Dr Duncan Still, a GP with significant interest in integrative medicine. He highlights the importance of adopting a...

Red Light Holland CTIO to Unveil Groundbreaking iMicroapp Research Findings to Prestigious Drug Science Consortium

Toronto, Ontario–(Newsfile Corp. – July 9, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company”), a...

Red Light Holland Partners with Professor David Nutt and Drug Science to Analyze iMicroapp Data and Promote Responsible Regulations For Psilocybin Microdosing

Toronto, Ontario–(Newsfile Corp. – April 4, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company”), a...

100. 100 Years of the Maudsley Hospital with Dr James Rucker

On the 100th Episode of the Drug Science podcast, Prof David Nutt meets with Dr James Rucker to celebrate the 100th anniversary of Maudsley Hospital....

PT490 – Dr. Robin Carhart-Harris – Plasticity, the Role of Set and Setting, and the Influence of Psychedelics

In this episode, Joe interviews Dr. Robin Carhart-Harris: founder and head of the Centre for Psychedelic Research at Imperial College London, founding director of the...

96. Ayahuasca: Before and After with Evgeny Lebedev

In this episode, David Nutt meets with Evgeny Lebedev, owner of the Independent and Evening Standard newspaper. Lebedev shares his transformative journey during his first...

92. Psilocybin for Gambling Addiction with Dr Rayyan Zafar

In the first of our LIVE Psilocybin Series, David Nutt speaks to Rayyan Zafar a final year PhD student at Imperial College London. Rayyan discusses...

The benefits of medical psychedelics: 'For many people, one supervised trip resets everything'

As the debate on psychedelics such as psilocybin moves from research labs to mainstream public consciousness, Professor David Nutt explains how ...

89. David Vs David with Dr David Erritzoe

Recorded live from the launch event of David Nutt's latest book, "Psychedelics: The Revolutionary Drugs That Could Change Your Life – a guide from the...

Why Is Khat Illegal?

In the region where it originated, it’s known as “the flower of paradise.” Khat, a shrub known for the stimulant-like effect it produces when chewed,...

Psychedelics by David Nutt review – hope or hype? | Science and nature books

An expert makes the case for psychedelic therapy, but we should beware the 'Pollan effect'

79. Smoking vs Vaping with Dr Alex Wodak

In this week’s episode, join Professor David Nutt as he engages in a thought-provoking conversation with Dr Alex Wodak, an internationally renowned authority on harm...

Psychedelic Researchers in Europe Proceed with Caution

This article originally appeared on Psychedelic Alpha. Founded by Josh Hardman, Psychedelic Alpha is an independent website, newsletter and community that is devoted to empowering...

Drug Science LIVE - Part 2

This week we present you with part 2 of the podcast recorded live at the book launch of 'Drug Science and British Drug Policy’. We’re...

Drug Science LIVE - Part 1

This week we present you with a podcast recorded live at the book launch of ‚Drug Science and British drug policy’. We’re going to hear...

Meet the doctor who changed the TGA's mind on psychedelics | AusDoc

Psychedelic medicine 'is not some sort of blissful journey to meet God,' says Professor David Nutt. Professor David Nutt is unapologetic for ...

Psychedelic Legend Amanda Feilding is Turning 80—And Her Retreats are Open for Business

*This article is sponsored by Beckley Retreats. Even five years ago, as the waves of the western psychedelic resurgence developed a steady ripple, it remained...

Revitalist's Kathryn Walker and Awakn's Prof. David Nutt to Host Webinar on ... - Financial Post

David Nutt to discuss ketamine-assisted therapy for Veterans suffering with Addictions in a live webinar. Financial Post Top Stories Banner ...

Revitalist's Kathryn Walker and Awakn's Prof. David Nutt to Host Webinar on Ketamine ...

David Nutt to discuss ketamine-assisted therapy for Veterans suffering with Addictions in a live webinar. “Of the 1.1 million veterans living with ...

New Survey Shows Psychedelic Use At Record High

Psychedelia has been busy stamping its imprint on the collective consciousness. Between Netflix series, books, podcasts, and shroom-themed yoga tights, you’d have to be living...

The Drug Enforcement Agency listens to psychedelic experts - drugscience.org.uk

By Professor David Nutt and James Bunn. The Drug Enforcement Agency (DEA) recently withdrew a proposal to ban five psychedelic substances:.

PT334 – Prof. David Nutt – The Human Brain, Addiction, and Telling the Truth About Drugs

In this episode, David interviews David Nutt: Psychiatrist, Founder/Chief Scientific Officer at Drug Science, Chief Research Officer at Awakn Life Sciences, and Professor of Neuropsychopharmacology...

PT334 – Prof. David Nutt – The Human Brain, Addiction, and Telling the Truth About Drugs

In this episode, David Drapkin interviews David Nutt: Psychiatrist, Founder and Chief Scientific Officer at Drug Science, Chief Research Officer at Awakn Life Sciences, and...

Launch of the Psychedelic Access and Research European Alliance – PAREA

Official launch of the Psychedelic Access and Research European Alliance – PAREA PAREA is a non-profit, multistakeholder and multidisciplinary partnership bringing together patient organizations, medical...

Nutt Uncut: Conversation with Professor David Nutt

Jan 20, 2021

Psilocybin and Depression

Severe Depression

Start Date: Sep 2018

Last Updated: Dec 2017

Psilocybin Ketamine

Last updated: Mar 25, 2021

Request Deletion